219 related articles for article (PubMed ID: 7580358)
1. Antifibrinolytic therapy in cardiac surgery.
Chen RH; Frazier OH; Cooley DA
Tex Heart Inst J; 1995; 22(3):211-5. PubMed ID: 7580358
[TBL] [Abstract][Full Text] [Related]
2. Intraoperative antifibrinolysis and blood-saving techniques in cardiac surgery. Prospective trial of 3 antifibrinolytic drugs.
Penta de Peppo A; Pierri MD; Scafuri A; De Paulis R; Colantuono G; Caprara E; Tomai F; Chiariello L
Tex Heart Inst J; 1995; 22(3):231-6. PubMed ID: 7580360
[TBL] [Abstract][Full Text] [Related]
3. Coronary artery bypass grafting after aprotinin: are we doing better?
Beckerman Z; Shopen Y; Alon H; Cohen O; Nir RR; Adler Z; Bolotin G
J Thorac Cardiovasc Surg; 2013 Jan; 145(1):243-8. PubMed ID: 23072702
[TBL] [Abstract][Full Text] [Related]
4. The use of low-dose aprotinin, epsilon-aminocaproic acid or tranexamic acid for prevention of mediastinal bleeding in patients receiving aspirin before coronary artery bypass operations.
Landymore RW; Murphy JT; Lummis H; Carter C
Eur J Cardiothorac Surg; 1997 Apr; 11(4):798-800. PubMed ID: 9151061
[TBL] [Abstract][Full Text] [Related]
5. Antifibrinolytic therapy during cardiopulmonary bypass reduces proinflammatory cytokine levels: a randomized, double-blind, placebo-controlled study of epsilon-aminocaproic acid and aprotinin.
Greilich PE; Brouse CF; Whitten CW; Chi L; Dimaio JM; Jessen ME
J Thorac Cardiovasc Surg; 2003 Nov; 126(5):1498-503. PubMed ID: 14666025
[TBL] [Abstract][Full Text] [Related]
6. Is epsilon-aminocaproic acid as effective as aprotinin in reducing bleeding with cardiac surgery?: a meta-analysis.
Munoz JJ; Birkmeyer NJ; Birkmeyer JD; O'Connor GT; Dacey LJ
Circulation; 1999 Jan 5-12; 99(1):81-9. PubMed ID: 9884383
[TBL] [Abstract][Full Text] [Related]
7. The safety of aprotinin and lysine-derived antifibrinolytic drugs in cardiac surgery: a meta-analysis.
Henry D; Carless P; Fergusson D; Laupacis A
CMAJ; 2009 Jan; 180(2):183-93. PubMed ID: 19050037
[TBL] [Abstract][Full Text] [Related]
8. The effect of antifibrinolytic prophylaxis on postoperative outcomes in patients undergoing cardiac operations.
Koul A; Ferraris V; Davenport DL; Ramaiah C
Int Surg; 2012; 97(1):34-42. PubMed ID: 23101999
[TBL] [Abstract][Full Text] [Related]
9. Removal of aprotinin from low-dose aprotinin/tranexamic acid antifibrinolytic therapy increases transfusion requirements in cardiothoracic surgery.
Vonk AB; Meesters MI; Schats J; Romijn JW; Jansen EK; Boer C
Interact Cardiovasc Thorac Surg; 2011 Feb; 12(2):135-9. PubMed ID: 21075830
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of aprotinin, epsilon aminocaproic acid, or combination in cyanotic heart disease.
Chauhan S; Kumar BA; Rao BH; Rao MS; Dubey B; Saxena N; Venugopal P
Ann Thorac Surg; 2000 Oct; 70(4):1308-12. PubMed ID: 11081890
[TBL] [Abstract][Full Text] [Related]
11. High-dose epsilon-aminocaproic acid versus aprotinin: antifibrinolytic efficacy in first-time coronary operations.
Eberle B; Mayer E; Hafner G; Heinermann J; Dahm M; Prellwitz W; Dick W; Oelert H
Ann Thorac Surg; 1998 Mar; 65(3):667-73. PubMed ID: 9527193
[TBL] [Abstract][Full Text] [Related]
12. Conference discussion: Removal of aprotinin from low-dose aprotinin/tranexamic acid antifibrinolytic therapy increases transfusion requirements in cardiothoracic surgery.
Wahba A; Vonk A; Bidstrup B
Interact Cardiovasc Thorac Surg; 2011 Feb; 12(2):139-40. PubMed ID: 21322159
[No Abstract] [Full Text] [Related]
13. Epsilon aminocaproic acid reduces blood transfusion and improves the coagulation test after pediatric open-heart surgery: a meta-analysis of 5 clinical trials.
Lu J; Meng H; Meng Z; Sun Y; Pribis JP; Zhu C; Li Q
Int J Clin Exp Pathol; 2015; 8(7):7978-87. PubMed ID: 26339364
[TBL] [Abstract][Full Text] [Related]
14. Antifibrinolytic Drugs for the Prevention of Bleeding in Pediatric Cardiac Surgery on Cardiopulmonary Bypass: A Systematic Review and Meta-analysis.
Siemens K; Sangaran DP; Hunt BJ; Murdoch IA; Tibby SM
Anesth Analg; 2022 May; 134(5):987-1001. PubMed ID: 34633994
[TBL] [Abstract][Full Text] [Related]
15. Postoperatively administered aprotinin or epsilon aminocaproic acid after cardiopulmonary bypass has limited benefit.
Ray MJ; Hales MM; Brown L; O'Brien MF; Stafford EG
Ann Thorac Surg; 2001 Aug; 72(2):521-6. PubMed ID: 11515892
[TBL] [Abstract][Full Text] [Related]
16. Putting the record straight on aprotinin as safe and effective: results from a mixed treatment meta-analysis of trials of aprotinin.
Howell N; Senanayake E; Freemantle N; Pagano D
J Thorac Cardiovasc Surg; 2013 Jan; 145(1):234-40. PubMed ID: 22889481
[TBL] [Abstract][Full Text] [Related]
17. Antifibrinolytic agents in current anaesthetic practice.
Ortmann E; Besser MW; Klein AA
Br J Anaesth; 2013 Oct; 111(4):549-63. PubMed ID: 23661406
[TBL] [Abstract][Full Text] [Related]
18. Limiting excessive postoperative blood transfusion after cardiac procedures. A review.
Ferraris VA; Ferraris SP
Tex Heart Inst J; 1995; 22(3):216-30. PubMed ID: 7580359
[TBL] [Abstract][Full Text] [Related]
19. Tranexamic acid compared with high-dose aprotinin in primary elective heart operations: effects on perioperative bleeding and allogeneic transfusions.
Casati V; Guzzon D; Oppizzi M; Bellotti F; Franco A; Gerli C; Cossolini M; Torri G; Calori G; Benussi S; Alfieri O
J Thorac Cardiovasc Surg; 2000 Sep; 120(3):520-7. PubMed ID: 10962414
[TBL] [Abstract][Full Text] [Related]
20. Cost-benefit and efficacy of aprotinin compared with epsilon-aminocaproic acid in patients having repeated cardiac operations: a randomized, blinded clinical trial.
Bennett-Guerrero E; Sorohan JG; Gurevich ML; Kazanjian PE; Levy RR; Barberá AV; White WD; Slaughter TF; Sladen RN; Smith PK; Newman MF
Anesthesiology; 1997 Dec; 87(6):1373-80. PubMed ID: 9416723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
